• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Genelux Corporation

    6/22/26 4:45:20 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNLX alert in real time by email
    false 0001231457 0001231457 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 16, 2026

     

     

     

    Genelux Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-41599   77-0583529

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

       

    2625 Townsgate Road, Suite 230

    Westlake Village, California

      91361
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (805) 267-9889

     

    Not Applicable

    (Former name or former address, if changed since last report.)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, par value $0.001 per share   GNLX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

     

     

     

     

     

     

    5.07 Submission of Matters to a Vote of Security Holders.

     

    On June 16, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 17, 2026, the record date for the Annual Meeting (the “Record Date”), 44,842,243 shares of the Company’s Common Stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

     

    A total of 28,263,200 shares of the Company’s Common Stock were present at the Annual Meeting in person, by virtual attendance or by proxy, which represents approximately 63.03% of the shares of the Company’s Common Stock outstanding as of the Record Date.

     

    Proposal 1. Election of Directors.

     

    The Company’s stockholders elected the person listed below as the Class I Director, to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successor is duly elected and qualified or until their earlier death, resignation or removal. The final voting results are as follows:

     

    Name   Votes For   Votes Withheld   Broker Non-Votes
    John Smither   8,696,891   3,393,408   16,172,901

     

    Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm.

     

    The Company’s stockholders ratified the selection of Weinberg & Company, P.A. by the Audit Committee of the Board as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    28,092,768   105,158   65,274   0

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Genelux Corporation
         
    Date: June 22, 2026 By: /s/ Thomas Zindrick, J.D.
        Thomas Zindrick, J.D.
        President and Chief Executive Officer

     

     

    Get the next $GNLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNLX

    DatePrice TargetRatingAnalyst
    10/21/2025$16.00Buy
    Lake Street
    10/29/2024$8.00Buy
    Guggenheim
    8/28/2024$10.00Buy
    ROTH MKM
    11/27/2023$35.00Buy
    H.C. Wainwright
    9/12/2023$40.00Buy
    Maxim Group
    2/15/2023$10.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $GNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Genelux with a new price target

    Lake Street initiated coverage of Genelux with a rating of Buy and set a new price target of $16.00

    10/21/25 7:59:44 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Genelux with a new price target

    Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00

    10/29/24 6:26:41 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Genelux with a new price target

    ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00

    8/28/24 7:46:18 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Zindrick Thomas was granted 730,601 shares, increasing direct ownership by 137% to 1,263,913 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/18/26 7:05:17 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Groen Eric was granted 233,957 shares (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/18/26 7:05:21 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thomas John was granted 28,409 shares, increasing direct ownership by 6% to 501,193 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/18/26 7:05:16 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    SEC Filings

    View All

    SEC Form 8-K filed by Genelux Corporation

    8-K - GENELUX Corp (0001231457) (Filer)

    6/22/26 4:45:20 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Genelux Corporation

    10-Q - GENELUX Corp (0001231457) (Filer)

    5/7/26 4:07:52 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Genelux Corporation

    DEFA14A - GENELUX Corp (0001231457) (Filer)

    4/29/26 8:05:21 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $GNLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

    -- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 -- -- $26.3 million in cash, cash equivalents, marketable securities and restricted cash as of March 31, 2026; expected to fund operations into 1Q27 -- WESTLAKE VILLAGE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2026 and provided general business updates. "As we build on our momentum entering 2026, we remain focused on disciplined exec

    5/7/26 4:15:00 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC); additional updates expected throughout 2026 -- -- Appointed Jason Litten, M.D., as Chief Medical Officer to lead clinical development strategy -- -- $33.1 million in pro forma cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025, including $18.5 million in net proceeds from underwritten offering of common stock in January 2026; expected to su

    3/19/26 4:15:00 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation to Participate in Upcoming Conferences

    WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences. Oppenheimer Healthcare Life Sciences Conference: Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat on Wednesday, February 25, 2026, at 11:20 a.m. ET.TD Cowen 46th Annual Health Care Conference: Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, Chief Financial Officer, will participate in a presentation on Monda

    2/18/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyree James L bought 6,250 shares, increasing direct ownership by 181% to 9,710 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:20 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thomas John bought 2,500 shares, increasing direct ownership by 0.54% to 465,960 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:16 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smither John W bought 6,250 shares, increasing direct ownership by 90% to 13,170 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:18 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Leadership Updates

    Live Leadership Updates

    View All

    Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. "We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes," said Thomas Zindrick, President, CEO, and Chairman of the Board. "He brings extensive experience in oncology drug development of innovati

    1/2/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

    WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum continued to build across the Company, as it looks forward to a series of key clinical readouts over the next year. These readouts are intended to further demonstrate the ability of Olvi-Vec to resensitize tumors to frontline platinum-based regimens. Genelux continues to advance Olvi-Vec toward potential registration in platinum-resistant/refractory ovarian cancer (PRROC) with topline data expected in the first half of 2026. Earlier this

    8/7/25 4:20:00 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

    WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025. "We are delighted to welcome Eric to the executive team," said Thomas Zindrick, President, CEO, and Chairman of the Board. "Eric brings a powerful blend of legal expertise, global business development savvy, and a strategic understanding of the biotechnology ecosystem. His proven ability to lead high-impact transactions, build trusted partnerships, and navigate complex regulatory

    7/7/25 7:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    6/10/24 12:35:45 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Genelux Corporation

    SC 13G - GENELUX Corp (0001231457) (Subject)

    10/25/24 9:45:20 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Genelux Corporation

    SC 13G/A - GENELUX Corp (0001231457) (Subject)

    10/22/24 4:12:19 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genelux Corporation

    SC 13G - GENELUX Corp (0001231457) (Subject)

    2/2/24 4:06:25 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care